Navigation Links
For Atrial Fibrillation, Surveyed Experts Indicate That Multaq, Celivarone and ATI-2042 Have Advantages Over Propafenone in the Maintenance of Normal Sinus Rhythm
Date:4/21/2009

Multaq Will Earn Decision Resources' Clinical Gold Standard Status for Atrial Fibrillation in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., April 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in maintenance of normal sinus rhythm in atrial fibrillation. Clinical data and the opinions of interviewed thought leaders indicate that Sanofi-Aventis's Multaq and celivarone, and Aryx Therapeutics' ATI-2042 have advantages in this attribute over propafenone (GlaxoSmithKline/Abbott's Rythmol/Rythmonorm, generics), the sales-leading antiarrhythmic agent in the market.

The new report entitled Atrial Fibrillation: Opportunity Awaits Antiarrhythmics with Improved Safety and Anticoagulants Without Routine Monitoring also finds that an anticoagulant for the prevention of stroke in atrial fibrillation that does not require routine monitoring would earn a 53 percent patient share in the United States and a 55 percent patient share in Europe, according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for the maintenance of normal sinus rhythm in atrial fibrillation was amiodarone (Sanofi-Aventis/Wyeth's Cordarone, generics). Based on available data and expert opinion, Multaq will earn gold standard status for maintenance of normal sinus rhythm in atrial fibrillation in 2012, following its approval for the indication in 2009. Additionally, following its approval in 2014, ATI-2042 will earn gold-standard status for the indication in 2017.

"Multaq and ATI-2042 have competitive advantages over other emerging therapies because they have been designed to have efficacy similar to that of amiodarone but without its side effects," said Decision Resources Analyst Samira Benyoucef, Ph.D. "Because they are free of thyroid and pulmonary toxicity--the main adverse effects constraining amiodarone's widespread use--Multaq and ATI-2042 offer a significant safety advantage over amiodarone."

About the Report

Atrial Fibrillation: Opportunity Awaits Antiarrhythmics with Improved Safety and Anticoagulants Without Routine Monitoring is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Larger Men at Greater Risk for Atrial Fibrillation
2. Big men more susceptible to atrial fibrillation
3. For Prevention of Stroke, Surveyed Cardiologists and PCPs Expect to Prescribe Xarelto to Approximately One-Third of Newly-Diagnosed Atrial Fibrillation Patients
4. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
5. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
6. Austin, Texas, Physicians Second in Nation to Perform New Procedure for Difficult-to-Treat Atrial Fibrillation Cases
7. Increasing Use of Ablation to Treat Atrial Fibrillation
8. Defect in Gene Tied to Atrial Fibrillation
9. Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
10. Innovative Atrial Fibrillation (AF) Catheter Ablation System From Ablation Frontiers is Subject of Two Abstracts at Heart Rhythm Congress UK
11. Novel imaging approach may assist in predicting success of treatment for atrial fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , ... recently partnered with Heart City Health Center to improve access to ... Heart City Health Center has provided the Elkhart community with access to high ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to stabilize critical ... leave patients with dental emergencies at risk of losing a tooth or their smiles. ... , Common dental emergencies include:, , Avulsed or knocked-out ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Ongoing news of ... Life Care Association™ (ALCA) to conduct a survey that takes a closer look at ... today illustrates the prevalence and causes of TBI among the aging population, and identifies ...
(Date:2/10/2016)... , ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: ... report results for the fourth quarter and full year ended December 31, 2015 on ... conference call and webcast for the investment community following the release at 4:30 PM ...
(Date:2/10/2016)... ... 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves ... The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp explains ... is March 16, 2016. A free review copy is available to the media ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... MOUNTAIN VIEW, Calif. , Feb. 10, ... result of a synergistic confluence of various ... unique value propositions, previously unavailable. These opportunities ... convergence and convergence, in turn, drives the ... Today,s entrepreneurial scenario is characterized by technology ...
(Date:2/10/2016)... Jersey and OR AKIVA, Israel ... Regentis Biomaterials Ltd., a leader in the ... Series D investment round on February 5, 2016. The ... Group ("Haisco"), a leading Chinese pharmaceutical manufacturer, and ... SCP Vitalife Partners, Generali Financial Holdings and both the ...
(Date:2/10/2016)... ALSP, Inc. announced that it has appointed Col.(Retired) Dallas ... preparation for its move into clinical trials with its lead ... are pleased to welcome Dallas Hack onto the ... of such practical knowledge and far-reaching experience in Traumatic Brain ... broad experience and success as a clinician and researcher in ...
Breaking Medicine Technology: